---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-207537"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:33:24.739566+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# EyePoint Q1 net loss $84.8M ($0.99/share); DURAVYU Phase 3 wet AMD data expected mid-2026

## Summary
- Q1 2026 revenue $0.7M vs $24.5M YoY, driven by YUTIQ license deferral; operating expenses $87.9M.
- Cash & investments $223M at March 31, 2026, runway into Q4 2027; down from $306M at year-end 2025.
- Phase 3 wet AMD trials (LUGANO/LUCIA) topline data due mid-2026; over 900 patients enrolled.
- Phase 3 DME trials (COMO/CAPRI) >1/3 enrolled; full enrollment expected Q3 2026, topline Q4 2027.
- New ARVO 2026 data show vorolanib inhibits JAK1/IL-6, supporting multi-mechanism anti-inflammatory effect.

## SEC filing metadata
- accession: 0001193125-26-207537
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312526207537/0001193125-26-207537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312526207537/eypt-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-207537
- JSON: https://secwatch.observer/filing/0001193125-26-207537.json
- Plain text: https://secwatch.observer/filing/0001193125-26-207537.txt

## Source-grounded claims
- claim_id: a3ae0033ce439c22c098cafa754585cc7c8148ab
  claim: EyePoint, Inc. reported first quarter ended March 31, 2026 results: revenue $0.7 million, net income net loss was $84.8 million, EPS ($0.99) per share.
  evidence_excerpt: or DURAVYU-related ocular or systemic SAEs. Review of Results for the First Quarter Ended March 31, 2026 For the first quarter ended March 31, 2026, total net revenue was $0.7 million compared to $24.5 million for the corresponding period in 2025. The decrease was primarily driven by the recognition of remaining deferred revenue related to the Company’s 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000119312526207537/0001193125-26-207537-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.